
Privacy notice | Accessibility statement | Terms and conditions | Login | Contact |
UK data driving real-world evidence
Bibliography
Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,700 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 4 March 2021) and papers are listed below and in the PDF below.
If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.
Download:
(PDF, 5MB, 224 pages)This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website.
“5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study”, Gut, vol. 54, pp. 1573-8, 2005.
, “5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study”, Gastroenterology, vol. 126, pp. 1733-9, 2004.
, “Angiotensin-converting enzyme inhibitor use and protection against pneumonia in patients with diabetes”, J Hypertens, vol. 25, pp. 235-9, 2007.
, “Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications”, Eur J Clin Pharmacol, vol. 70, pp. 849-57, 2014.
, “Anti-osteoporosis drug prescribing after hip fracture in the UK: 2000-2010”, Osteoporos Int, vol. 26, pp. 1919-28, 2015.
, “Are inhaled corticosteroids associated with an increased risk of fracture in children?”, Osteoporos Int, vol. 15, pp. 785-91, 2004.
, “Bone fracture risk is not associated with the use of glucagon-like peptide-1 receptor agonists: a population-based cohort analysis”, Calcif Tissue Int, vol. 97, pp. 104-12, 2015.
, “Causes of death in patients with multiple sclerosis and matched referent subjects: a population-based cohort study”, Eur J Neurol, vol. 19, pp. 1007-14, 2012.
, “Changes in the characteristics of patients prescribed selective cyclooxygenase 2 inhibitors after the 2004 withdrawal of rofecoxib”, Arthritis Rheum, vol. 59, pp. 1105-11, 2008.
, “Children and the risk of fractures caused by oral corticosteroids”, J Bone Miner Res, vol. 18, pp. 913-8, 2003.
, “Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis”, Arthritis Rheum, vol. 54, pp. 3104-12, 2006.
, “Comparative Performance of ATRIA, CHADS2, and CHA2DS2-VASc Risk Scores Predicting Stroke in Patients With Atrial Fibrillation: Results From a National Primary Care Database”, J Am Coll Cardiol, vol. 66, pp. 1851-9, 2015.
, “A comparison of cost effectiveness using data from randomized trials or actual clinical practice: selective cox-2 inhibitors as an example”, PLoS Med, vol. 6, p. e1000194, 2009.
, “Difference in risks of allergic reaction to sulfonamide drugs based on chemical structure”, Ann Pharmacother, vol. 40, pp. 1040-6, 2006.
, “Does a fracture at one site predict later fractures at other sites? A British cohort study”, Osteoporos Int, vol. 13, pp. 624-9, 2002.
, “Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction?”, J Intern Med, vol. 264, pp. 481-92, 2008.
, “Epidemiology of childhood fractures in Britain: a study using the general practice research database”, J Bone Miner Res, vol. 19, pp. 1976-81, 2004.
, “Epidemiology of fractures in England and Wales”, Bone, vol. 29, pp. 517-22, 2001.
, “Evaluating drug toxicity signals: is a hierarchical classification of evidence useful or a hindrance?”, Pharmacoepidemiol Drug Saf, vol. 17, pp. 475-84, 2008.
, “Fracture rate in patients with myasthenia gravis: the general practice research database”, Osteoporos Int, vol. 24, pp. 467-76, 2013.
, “Fracture risk with intermittent high-dose oral glucocorticoid therapy”, Arthritis Rheum, vol. 56, pp. 208-14, 2007.
, “The Impact of the Choice of Data Source in Record Linkage Studies Estimating Mortality in Venous Thromboembolism”, PLoS One, vol. 11, p. e0148349, 2016.
, “Incidence and natural history of Paget's disease of bone in England and Wales”, J Bone Miner Res, vol. 17, pp. 465-71, 2002.
, “Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids”, Rheumatology (Oxford), vol. 46, pp. 460-6, 2007.
, “Individualizing the risks and benefits of postmenopausal hormone therapy”, Menopause, vol. 15, pp. 374-81, 2008.
, “Insulin glargine use and breast cancer risk: Associations with cumulative exposure”, Acta Oncol, vol. 55, pp. 851-8, 2016.
, “Lithium use and the risk of fractures”, Bone, vol. 40, pp. 1252-8, 2007.
, “Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: A retrospective population-based cohort study”, Diabetes Obes Metab, vol. 19, pp. 421-428, 2017.
, “Mortality in British hip fracture patients, 2000-2010: a population-based retrospective cohort study”, Bone, vol. 66, pp. 171-7, 2014.
, “Neutropenia and agranulocytosis in England and Wales: incidence and risk factors”, Am J Hematol, vol. 72, pp. 248-54, 2003.
, “Oral corticosteroids and fracture risk: relationship to daily and cumulative doses”, Rheumatology (Oxford), vol. 39, pp. 1383-9, 2000.
, “The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non-valvular atrial fibrillation”, J Thromb Haemost, vol. 11, pp. 107-15, 2013.
, “Patterns of risk of cancer in patients with metal-on-metal hip replacements versus other bearing surface types: a record linkage study between a prospective joint registry and general practice electronic health records in England”, PLoS One, vol. 8, p. e65891, 2013.
, “Predicting the 10-year risk of hip and major osteoporotic fracture in rheumatoid arthritis and in the general population: an independent validation and update of UK FRAX without bone mineral density”, Ann Rheum Dis, vol. 75, pp. 2095-2100, 2016.
, “Psychiatric and cardiovascular comorbidities in patients with diabetes mellitus starting antiobesity drugs”, Obesity (Silver Spring), vol. 16, pp. 2331-5, 2008.
, “Public health impact of adverse bone effects of oral corticosteroids”, Br J Clin Pharmacol, vol. 51, pp. 601-7, 2001.
, “Remission of Type 2 Diabetes Mellitus in Patients After Different Types of Bariatric Surgery: A Population-Based Cohort Study in the United Kingdom”, JAMA Surg, vol. 150, pp. 1126-33, 2015.
, “Risk of aplastic anemia in patients using antiepileptic drugs”, Epilepsia, vol. 47, pp. 1232-6, 2006.
, “Risk of cataract and glaucoma in patients with multiple sclerosis”, Mult Scler, vol. 18, pp. 628-38, 2012.
, “The risk of colorectal cancer in patients with type 2 diabetes: associations with treatment stage and obesity”, Diabetes Care, vol. 38, pp. 495-502, 2015.
, “Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data”, PLoS One, vol. 6, p. e28157, 2011.
, “Risk of fracture in patients with Charcot-Marie-Tooth disease”, Muscle Nerve, vol. 50, pp. 919-24, 2014.
, “Risk of fracture in patients with Guillain-Barre syndrome”, Osteoporos Int, vol. 25, pp. 1845-51, 2014.
, “The risk of fracture in patients with multiple sclerosis: the UK general practice research database”, J Bone Miner Res, vol. 26, pp. 2271-9, 2011.
, “Risk of fracture in patients with muscular dystrophies”, Osteoporos Int, vol. 25, pp. 509-18, 2014.
, “Risk of fracture with thiazolidinediones: an individual patient data meta-analysis”, Front Endocrinol (Lausanne), vol. 4, p. 11, 2013.
, “Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study”, Bmj, vol. 354, p. i3625, 2016.
, “Risk of infections in patients with gout: a population-based cohort study”, Sci Rep, vol. 7, p. 1429, 2017.
, “The risk of major and any (non-hip) fragility fracture after hip fracture in the United Kingdom: 2000-2010”, Osteoporos Int, vol. 25, pp. 2555-63, 2014.
, “The risk of venous thromboembolism in patients with multiple sclerosis: the Clinical Practice Research Datalink”, J Thromb Haemost, vol. 12, pp. 444-51, 2014.
,